

Third Annual Hematologic Malignancy Symposium

SATURDAY, MARCH 13, 2021

Morning sessions

8 am – 8:05am	Welcome by symposium chairs – co-chairs
<i>Molecular Basis of Clonal Hematopoiesis</i>	
8:05am – 8:25am	Infection as a driver of Dnmt3a-loss of function clonal hematopoiesis Speaker: <i>Katherine Y. King MD, PhD</i> <i>Baylor College of Medicine, Houston, TX</i>
8:30am – 8:50am	FEATURED LECTURE Evaluating mutations in healthy blood Speaker: <i>Caroline Watson, MD</i> <i>University of Cambridge, Cambridge, UK.</i>
8:55am – 9:15am	Bone marrow failure in the elderly – from autoimmunity to clonality Speaker: <i>Phillip Scheinberg, MD</i> <i>Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil</i>
<i>Myelodysplasia and Chronic Myelomonocytic Leukemia</i>	
9:20am – 9:40am	Case based lecture on – Novel agents for LR-MDS Speaker: <i>Guillermo Garcia Manero, MD</i> <i>MD Anderson Cancer Center, Houston, TX</i>
9:45am – 10:05am	Understanding adaptive mechanism(s) of hypomethylating agents resistance Speaker: <i>Hetty Carraway, MD, MBA, FACP</i> <i>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH</i>
10:10am – 10:30am	What is the role of IDH inhibitors in myelodysplasia ? Speaker: <i>Andrew H. Wei, MBBS, PhD</i> <i>The Alfred Hospital, Melbourne, AUS</i>
10:35am – 10:55am	Chronic myelomonocytic leukemia (CMML) – Prime time for genomic driven management? Speaker: <i>Eric Padron, MD</i> <i>Lee Moffitt Cancer Center, Tampa Bay, FL</i>

BREAK

Acute Myelogenous Leukemia - Myeloid Directed Therapy

11:20am - 11:40am	FLT3 AML - current management Speaker: <i>Alexander E. Perl, MD</i> <i>University of Pennsylvania, Perelman Center for Advanced Medicine Philadelphia, PA</i>
11:45am - 12:05pm	Targeting BCL2 in AML Speaker: <i>Daniel A. Pollyea, MD, MS</i> <i>University of Colorado School of Medicine, Denver, CO</i>
12:10pm - 12:30pm	P53 directed myeloid therapies Speaker: <i>David Sallman, MD</i> <i>Lee Moffitt Cancer Center, Tampa Bay, FL</i>
BREAK POSTER EXHIBITS - POSTER PRESENTATION	
1:15pm - 1:35pm	What is the role of IDH inhibition in AML?? Speaker: <i>Courtney DiNardo, MD</i> <i>MD Anderson Cancer Center, Houston, TX</i>
Acute Myelogenous Leukemia - State-of-the-Art Lectures	
1:40pm - 2 pm	Post induction hypomethylating agents - insight from RELAZA trial Speaker: <i>Uwe Platzbecker, MD</i> <i>University Hospital, Leipzig, Germany</i>
2:05pm - 2:25pm	How to overcome FLT3 inhibition resistance Speaker: <i>Mark Levis, MD</i> <i>Johns Hopkins University, Baltimore, MD</i>
2:30pm - 2:50pm	How do I treat elderly AML patients? Speaker: <i>Gail J. Roboz, MD</i> <i>Weill Cornell Medical College, New York, NY</i>
BREAK	
3:15pm - 3:35pm	Panel discussion - Prime time - post induction AML maintenance, HMA vs targeted therapy or both? <i>Gail J. Roboz, M.D.</i> <i>Guillermo Garcia Manero, MD</i> <i>Mark Levis, MD</i> <i>David Sallman, MD</i>
3:40pm - 4 pm	Closing remarks - abstracts winners and 4th symposium announcements